Skip to main content

Advertisement

Table 1 Selected baseline characteristic of patients enrolled in SPRINT-2, all treatment arms combined [17]

From: Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

Characteristics Combined cohorts (N = 1097)
Race Cohort, no. (%)  
  Black 159 (14.5)
  Non-Black 938 (85.5)
Age, mean (standard deviation), years 49.1 (9.4)
Male sex, no. (%) 656 (60)
METAVIR Score, without missing data, no (%) N = 1060
  F0 – no fibrosis 47 (4.4)
  F1 – portal fibrosis without septa, 730 (68.9)
  F2 – portal fibrosis with few septa 183 (17.3)
  F3 – numerous septa without cirrhosis 47 (4.4)
  F4 – cirrhosis 53 (5)